Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

PURPOSE: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, “endogenous” biotin can interfere with the effectiveness of this approach by blocking binding of radiolabeled biot...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Park, Steven I., Shenoi, Jaideep, Frayo, Shani M., Hamlin, Donald K., Lin, Yukang, Wilbur, D. Scott, Stayton, Patrick S., Orgun, Nural, Hylarides, Mark, Buchegger, Franz, Kenoyer, Aimee L., Axtman, Amanda, Gopal, Ajay K., Green, Damian J., Pagel, John M., Press, Oliver W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3229652/
https://ncbi.nlm.nih.gov/pubmed/21976541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1204
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky